FDA approve Gilead’s breast cancer treatment after Phase III trial
April 8, 2021FDA, Gilead, Trodelvy, pharma, pharma news
The FDA has approved Gilead’s Trodelvy therapy for the treatment of metastatic triple-negative breast cancer (TNBC).
MHRA recommends AstraZeneca jab not be offered to under 30s
April 8, 2021The MHRA have recommended that people under the age of 30 not be offered the AstraZeneca COVID-19 vaccine, due to …
GBT publish successful results from sickle cell disease study
April 8, 2021Global Blood Therapeutics (GBT) have published the successful results from their Phase III study of Oxbryta (voxelotor) tablets in patients …
Collaboration announced to investigate COVID brain fog treatment
April 8, 2021Akili Interactive has announced a collaboration with Weill Cornell Medicine, New York-Presbyterian Hospital and Vanderbilt University Medical Center, to evaluate …
Intravac appoints Nathalie Laarakker as CFO
April 7, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Intravac have announced the appointment of Nathalie Laarakker as its new CFO and member of the company’s executive management team. …
Smithers promotes Nikki Lucas to Principal Project Manager
April 7, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Nikki Lucas has been appointed Principal Project Manager within Smithers’ Medical Device Physical Testing team. Lucas has over a decade …
New CEO appointed at Nordic Nanovector
April 7, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Nordic Nanovector have appointed Peter Braun as their new Chief Executive Officer. Braun is an experienced and entrepreneurial pharmaceutical leader, …
Ceryx Medical announce new chairman Chas Taylor
April 7, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Cardiovascular technology company Ceryx Medical have appointed Chas Taylor as their new chairman. The appointment comes at an interesting time …
Pharmafile.com’s weekly COVID-19 news round-up
April 7, 2021Research and Development COVID-19, COVID-19 vaccine, covid 19 news, covid-19 news, pharma, pharma news
The past week has seen plenty of COVID-19 vaccine news; AstraZeneca has halted the paediatric trial of their jab amid …
UK begins rollout of Moderna COVID-19 vaccine
April 7, 2021Research and Development COVID-19, COVID-19 vaccine, Moderna, Moderna vaccine, pharma, pharma news
The first Moderna COVID-19 vaccine in the UK has today been administered, beginning the rollout of the country’s third vaccine …
Novartis and Artios Pharma to collaborate on DDR cancer therapies
April 7, 2021Research and Development Novartis, RLT, oncology
Novartis and Artios Pharma have announced a global research collaboration to discover and validate next generation DNA damage response (DDR) …
AstraZeneca halt paediatric trial of COVID-19 vaccine amid blood clot probe
April 7, 2021Research and Development AstraZeneca, COVID-19, Vaccine
AstraZeneca has halted the trial of its COVID-19 vaccine on children aged between 6 and 17, while regulators investigate a …
NICE recommends CBT, acupuncture, and anti-depressants for chronic pain
April 7, 2021Research and Development NICE, antidepressant, chronic pain
A new NICE guideline on the assessment and management of chronic primary pain does not recommend the prescription of painkillers, …
Valneva’s inactivated COVID-19 vaccine candidate advances to Phase III trial
April 6, 2021Manufacturing and Production COVID-19, COVID-19 vaccine, Valneva, Valneva vaccine, inactivated vaccine
Specialty vaccine company Valneva’s inactivated COVID-19 jab has shown positive results in a Phase I/II trial, with a seroconversion rate …
Janssen agrees $780 million deal for authorisation of Cidara flu treatment
April 6, 2021Manufacturing and Production Janssen, cidara, influenza
Janssen has struck a deal worth up to $780 million with Cidara Therapeutics for exclusive worldwide rights to Cidara’s CD388 …
Pfizer vaccine 91.3% effective after six months, Phase III study shows
April 6, 2021Manufacturing and Production BioNTech, COVID-19, COVID-19 vaccine, Pfizer, Pfizer vaccine, pfizer-biontech vaccine
Pfizer and BioNTech’s follow-up study of their COVID-19 vaccine has confirmed the jab’s high efficacy after up to six months, …
Alnylam publish successful results from Phase III study of ultra-rare disease
April 6, 2021Manufacturing and Production
Alnylam Pharmaceuticals, a RNAi therapeutics company, have published successful results from their Phase III study of lumasiran, the first ever …
FDA approves first new ADHD drug in a decade
April 6, 2021Manufacturing and Production ADHD, FDA, paediatric
The FDA have approved the first new drug for the treatment of attention deficit hyperactivity disorder (ADHD) in over a …
Pharmafile.com’s top 10 news stories of the week
April 2, 2021COVID-19, covid 19 news, covid-19 news, news, news roundup, pharma news
In the last week, a number of new COVID-19 developments have emerged; Novavax has delayed 100 million vaccines to the …
EC grants marketing authorisation to Angelini Pharma’s epilepsy treatment
April 1, 2021Angelini Pharma have announced that the European Commission (EC) have granted marketing authorisation for Ontozry (cenobamate) for the treatment of …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
